Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 CAD | -1.84% | -8.57% | +10.34% |
May. 17 | XORTX Therapeutics Reprices Warrants Connected With U.S. IPO | MT |
May. 17 | XORTX Therapeutics Brief: Says Repriced Balance of Warrants Issued in Connection with October 2021 US IPO | MT |
Business Summary
Number of employees: 3
Managers
Managers | Title | Age | Since |
---|---|---|---|
Allen Davidoff
FOU | Founder | 64 | 18-01-08 |
Jim Fairbairn
DFI | Director of Finance/CFO | 65 | 18-11-05 |
Stephen Haworth
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
David MacDonald
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-19 |
Stacy Evans
PRN | Corporate Officer/Principal | - | 22-11-15 |
Brian Mangal
PRN | Corporate Officer/Principal | - | - |
Charlotte May
SEC | Corporate Secretary | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Paul van Damme
BRD | Director/Board Member | - | 18-01-24 |
Allen Davidoff
FOU | Founder | 64 | 18-01-08 |
Chairman | 67 | 22-06-05 | |
Raymond Pratt
BRD | Director/Board Member | 73 | 21-12-19 |
William Farley
BRD | Director/Board Member | 68 | 21-05-11 |
Patrick Treanor
BRD | Director/Board Member | - | Dec. 30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,903,565 | 2,807,176 ( 96.68 %) | 0 | 96.68 % |
Company contact information
Sector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.34% | 6.92M | |
+19.01% | 125B | |
+14.34% | 108B | |
-4.81% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.60% | 13.39B | |
+28.69% | 11.1B |
- Stock Market
- Equities
- XRTX Stock
- Company XORTX Therapeutics Inc.